The Reverse Split Is the Decoy

A company that sold its IPO shares at $4 per share in October is now asking to bundle 10 of its shares into 1 so it can pretend each one costs $4 again.

That's the math of Agroz Inc.'s proposed 1-for-10 reverse split — announced today as the centerpiece of a compliance plan after Nasdaq informed the Cayman Islands-registered vertical farming company that it will delist its stock.

The basic point is that the reverse split is not actually the story. It's the decoy. The real mechanism that matters is the filing delinquency: Agroz has not filed its annual report for the fiscal year ended December 31, 2025, and Nasdaq has already said it will not accept a compliance plan for that deficiency. A reverse split cannot cure a missing 20-F. No amount of share math makes an audit appear.

So let's look at the plumbing.

Nasdaq operates a tiered compliance machine for companies that fall below minimum listing standards. You get a deficiency letter, then a compliance window, then (if you're lucky) an extension, and finally a staff determination that effectively says the relationship is over unless you appeal. Agroz cycled through the first two stages twice.

The first deficiency came in February 2026 for the bid price problem. The stock had been trading below $1.00 per share for 30 consecutive business days, which violates Nasdaq Listing Rule 5550(a)(2). The company received an initial 180-day compliance period ending August 17, 2026. If Agroz had failed by that date, it could have qualified for a second 180-day extension — but only if it notified Nasdaq of its intention to cure the bid-price deficiency, potentially through a reverse stock split. That notification requirement is codified in Nasdaq Listing Rule 5810(c)(3)(A)(ii). Agroz never sent that notification.

In May, a second deficiency arrived. The company had failed to file its Form 20-F annual report for fiscal year 2025, violating Nasdaq Listing Rule 5250(c)(1). Nasdaq gave the company 60 days — until July 17 — to submit a compliance plan. It did not submit one.

Then on August 18, the Staff Determination Letter landed. Nasdaq cited both failures and, critically, noted that Agroz failed to notify it of its intention to cure the bid-price deficiency via a reverse split within the applicable period. The staff determination is the point of no return: trading would have been suspended at the open on August 27 had the company not filed a hearing request by August 25.

Agroz intends to file that hearing request today. The hearing stays the delisting while the panel deliberates. But here's where the two deficiencies split into very different problems.

The bid-price deficiency is a cosmetic issue. The stock is trading at roughly 29 cents. A 1-for-10 reverse split would mechanically push the per-share price toward $3 if the market cooperates. The company is finalizing a corporate-action application for the split and says it is subject to corporate, regulatory, and Nasdaq review. That's the straightforward part.

The filing delinquency is structural. Agroz has not completed an audit for its most recent fiscal year. Today's announcement says the company appointed Golden Eagle CPAs LLC, a US-based firm registered with the PCAOB, to expedite the audit and file the 20-F. The target is mid-October 2026. That's almost two months away, and Nasdaq has already said it will not accept an additional compliance plan for this deficiency under Rule 5810(c)(2)(A).

Nasdaq: We won't accept a plan for the filing issue.

Agroz: We have a plan.

That is the gap. The company is asking the hearing panel to grant relief that the listing rules explicitly say the staff would not provide. The hearing panel can do that, of course — hearings exist precisely to provide discretionary relief — but it makes the company's position more tenuous than the press release lets on.

There's also the equity requirement. Nasdaq's letter noted that the company failed to demonstrate compliance with minimum stockholders' equity requirements for initial listing. That's a separate listing standard that the company apparently never satisfied in the first place. A reverse split doesn't change total equity. And a filed 20-F doesn't create equity either — it just reveals how much (or how little) is there.

Let's step back and look at the whole machine.

Agroz raised approximately $5 million in gross proceeds from its IPO in October 2025, selling 1.25 million shares at $4.00 each. The offering was downsized from an initial plan of 2.5 million shares. A small offering from the start. The IPO price of $4 was barely above the $1 minimum bid price requirement in the first place — only four times the floor. That's not much buffer for a company whose stock has since fallen to roughly 29 cents.

The market cap today is in the neighborhood of $7 million. The stock has traded over $264,000 of volume today on about 820,000 shares. This is a micro-cap with thin liquidity, the exact profile that makes reverse splits both tempting and pointless.

Here's the thing about reverse splits in this context: they work as a mechanical fix but not as an economic one. The 1-for-10 split will reduce the number of outstanding shares and mechanically raise the per-share price. If 10 shares at $0.29 become 1 share, that share starts at $2.90. It could trade at $3, it could trade at $1.50. The split doesn't change the company's revenue, its losses, its operating economics, or the fact that someone needs to complete an audit that should have been done eight months ago.

Reverse splits also tend to attract a particular category of buyer: people who buy because the price is above $1 and the stock is still on Nasdaq, not because they've read the latest 20-F. (Which, in this case, doesn't exist yet.) Then, when the post-split stock drifts back below $1 — as these often do — the liquidity dries up and you're back at the same machine, only this time with a smaller number of shares outstanding and a more skeptical exchange.

The filing delinquency is the more revealing part of the story. An agricultural technology company that designs, builds, and operates controlled-environment vertical farms in Malaysia should have an auditable business. Revenue from farm construction, operations, management services, and produce sales — all visible in principle. The fact that the 20-F for fiscal year 2025 is still not filed suggests either operational complexity, auditor issues, or something that doesn't photograph well enough to put in a public filing.

Agroz says there can be no assurance that the hearing request will be successful or that it will regain compliance. That's standard boilerplate, but it's also the honest part of the release.

The hearing panel will look at two things: whether the company has a credible path to bid-price compliance (the reverse split makes that plausible on paper) and whether the filing delinquency will be resolved in time. Nasdaq's own position — that no compliance plan is acceptable for the filing issue — stacks against Agroz. The company is essentially asking the panel to override the staff's explicit position.

What this means for someone holding shares: the hearing stays the delisting, which buys time but doesn't resolve anything. If Agroz completes the audit, files the 20-F by mid-October, and executes the reverse split, the stock may remain listed. If the audit drags, the hearing panel denies relief, or Nasdaq finds new issues — which happens — the stock gets delisted and trades OTC, where liquidity is thinner and the reverse split accomplished nothing except making the remaining shares harder to sell.

The simplest model is this: Nasdaq's listing rules are designed to separate companies that are temporarily weak from companies that are structurally broken. The bid-price rule is the weak test. The filing requirement is the broken test. Agroz failed both, is proposing a fix for one, and is asking for a discretionary stay on the other. Whether the machine lets it through depends on whether the panel sees a temporary setback or something worse.

The filing should tell us which it is.